Evidence map›Paper›PMID 37486445›Full record

ArticleDigestive diseases and sciences2023

Neoplasia Diagnosis After Multi-target Stool DNA Is Enhanced Among Lowest Baseline Detectors.

Derek W Ebner, Kelli N Burger, Douglas W Mahoney, Brendan T Broderick, Jason D Eckmann, Mary E Devens, Kari L Lowrie, John B League, Jamie Bering, Allon Kahn and 9 more

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Digestive diseases and sciences, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.7field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 3 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors at 5 institutions in 1 country.

Derek W EbnerMayo Clinic, 200 First Street SW, Rochester, MN, 55905, USA.
Kelli N BurgerMayo Clinic, 200 First Street SW, Rochester, MN, 55905, USA.
Douglas W MahoneyMayo Clinic, 200 First Street SW, Rochester, MN, 55905, USA.
Brendan T BroderickMayo Clinic, 200 First Street SW, Rochester, MN, 55905, USA.
Jason D EckmannDivision of Gastroenterology, Hepatology, and Nutrition, University of Minnesota, Minneapolis, MN, USA.
Mary E DevensMayo Clinic, 200 First Street SW, Rochester, MN, 55905, USA.
Kari L LowrieMayo Clinic, 200 First Street SW, Rochester, MN, 55905, USA.
John B LeagueMayo Clinic, 200 First Street SW, Rochester, MN, 55905, USA.
Jamie BeringMayo Clinic, Scottsdale, AZ, USA.
Allon KahnMayo Clinic, Scottsdale, AZ, USA.
Eduardo A RodriguezDivision of Gastroenterology, Hepatology and Nutrition, University of Utah, Salt Lake City, UT, USA.
David O PrichardMayo Clinic, 200 First Street SW, Rochester, MN, 55905, USA.
Michael B WallaceMayo Clinic, Jacksonville, FL, USA.
Sunanda V KaneMayo Clinic, 200 First Street SW, Rochester, MN, 55905, USA.
Jonathan A LeightonMayo Clinic, Scottsdale, AZ, USA.
Navtej S ButtarMayo Clinic, 200 First Street SW, Rochester, MN, 55905, USA.
Lila J Finney RuttenMayo Clinic, 200 First Street SW, Rochester, MN, 55905, USA.
Suryakanth R GuruduMayo Clinic, Scottsdale, AZ, USA.
John B KisielMayo Clinic, 200 First Street SW, Rochester, MN, 55905, USA. kisiel.john@mayo.edu.ORCID 0000-0002-3840-5324
Mayo Clinic · USMayo Clinic in Arizona · USUniversity of Minnesota · USUniversity of Utah · USWinnMed · US

Funding

Minimally Invasive Molecular Approaches for the Detection of Barrett’s Esophagus and Esophageal AdenocarcinomaR01CA241164 · NCI · MAYO CLINIC ROCHESTER · PI Jagpreet Chhatwal, Prasad G. Iyer · 2019 to 2026
$3.9M
Multi-site Gastrointestinal Cancer Detection by Stool DNA MethylationR37CA214679 · NCI · MAYO CLINIC ROCHESTER · PI KISIEL, JOHN · 2018 to 2024
$2.8M
Multi-cancer Early DetectionR01CA214679 · NCI · MAYO CLINIC ROCHESTER · PI John Kisiel, Niloy Jewel Samadder · 2025 to 2026
$891k
NCI NIH HHS R01 CA214679NCI NIH HHS R37 CA214679
6 · The paper itself

Abstract

BACKGROUND AND

aimsVariation in colorectal neoplasia detection limits the effectiveness of screening colonoscopy. By evaluating neoplasia detection rates of individual colonoscopists, we aimed to quantify the effects of pre-procedural knowledge of a positive (+) multi-target stool DNA (mt-sDNA) on colonoscopy quality metrics.

methodsWe retrospectively identified physicians who performed a high volume of + mt-sDNA colonoscopies; colorectal neoplasia at post-mt-sDNA colonoscopy was recorded. These colonoscopists were stratified into quartiles based on baseline adenoma detection rates. Baseline colonoscopy adenoma detection rates and sessile serrated lesion detection rates were compared to post-mt-sDNA colonoscopy neoplasia diagnosis rates among each quartile. Withdrawal times were measured from negative exams.

resultsDuring the study period (2014-17) the highest quartile of physicians by volume of post-mt-sDNA colonoscopies were evaluated. Among thirty-five gastroenterologists, their median screening colonoscopy adenoma detection rate was 32% (IQR, 28-39%) and serrated lesion detection rate was 13% (8-15%). After + mt-sDNA, adenoma diagnosis increased to 47% (36-56%) and serrated lesion diagnosis increased to 31% (17-42%) (both p < 0.0001). Median withdrawal time increased from 10 (7-13) to 12 (10-17) minutes (p < 0.0001) and was proportionate across quartiles. After + mt-sDNA, lower baseline detectors had disproportionately higher rates of adenoma diagnosis in female versus male patients (p = 0.048) and higher serrated neoplasia diagnosis rates among all patients (p = 0.0092).

conclusionsKnowledge of + mt-sDNA enriches neoplasia diagnosis compared to average risk screening exams. Adenomatous and serrated lesion diagnosis was magnified among those with lower adenoma detection rates. Awareness of the mt-sDNA result may increase physician attention during colonoscopy. Pre-procedure knowledge of a positive mt-sDNA test improves neoplasia diagnosis rates among colonoscopists with lower baseline adenoma detection rates, independent of withdrawal time.

Indexed as

AdenomaColorectal NeoplasmsColonoscopyDNA, NeoplasmEarly Detection of CancerFemaleHumansMaleRetrospective StudiesDNA, NeoplasmBenchmarkingColonoscopyColorectal neoplasmsDNA methylationEarly detection of cancer

Identifiers

PMID37486445
PMCPMC10882559
OpenAlexW4385185928

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.